1-25 of 25
Keywords: statin
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Clin Sci (Lond) (2017) 131 (9): 791–797.
Published: 19 April 2017
...Allan D. Sniderman; Robert Scott Kiss; Thomas Reid; George Thanassoulis; Gerald F. Watts Statins and PCSK9 inhibitors dramatically lower plasma LDL levels and dramatically increase LDL receptor number within hepatocyte cell membranes. It seems self-evident that total clearance of LDL particles from...
Articles
Clin Sci (Lond) (2015) 128 (7): 411–423.
Published: 09 December 2014
..., which underlie vascular damage in diabetes. Statins are cholesterol-lowering drugs that are vasoprotective in diabetes through unknown mechanisms. We tested the hypothesis that atorvastatin decreases NADPH oxidase (Nox)-derived ROS generation and associated vascular injury in diabetes. Lepr db /Lepr db...
Includes: Supplementary data
Articles
Clin Sci (Lond) (2014) 126 (6): 401–415.
Published: 15 November 2013
...Philip J. Millar; John S. Floras Statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) reduce plasma cholesterol and improve endothelium-dependent vasodilation, inflammation and oxidative stress. A ‘pleiotropic’ property of statins receiving less attention is their effect on the autonomic...
Articles
Clin Sci (Lond) (2013) 124 (5): 343–349.
Published: 16 November 2012
... LDL) (syn LDL3; D =1.044–1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20±2 (means...
Articles
Articles
Articles
Clin Sci (Lond) (2011) 121 (9): 397–403.
Published: 12 July 2011
... with the significant rise in PCSK9 levels after statin therapy, warrant further studies in order to unravel the exact role of PCSK9 in the pathogenesis and treatment of this highly prevalent genetic dyslipidaemia. Subjects were weighed in their underwear. BMI (body mass index) was calculated as weight divided...
Articles
Articles
Articles
Articles
Articles
Articles
Clin Sci (Lond) (2009) 116 (6): 493–495.
Published: 12 February 2009
... s.wort@imperial.ac.uk ). 13 11 2008 27 11 2008 27 11 2008 © The Authors Journal compilation © 2009 Biochemical Society 2009 chronic obstructive pulmonary disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin COPD (chronic...
Articles
Clin Sci (Lond) (2009) 116 (6): 497–505.
Published: 12 February 2009
... disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin Pulmonary function indices at baseline and at the end of the study were performed according to American Thoracic Society standards [ 11 ]. We used an FEV 1 /FVC ratio of <0.70 to define airflow...
Articles
Clin Sci (Lond) (2008) 115 (1): 35–42.
Published: 02 June 2008
...Zhen Huang; Leif Jansson; Åke Sjöholm Patients with diabetes are often treated with a statin for hyperlipidaemia and an ACE (angiotensin-converting enzyme) inhibitor or angiotensin receptor antagonist for hypertension or albuminuria. These drugs may also exert beneficial metabolic effects, causing...
Articles
Clin Sci (Lond) (2007) 113 (3): 119–127.
Published: 02 July 2007
...Jennifer H. Martin; Henry Krum HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors (statins) are well-established therapies in the prevention and treatment of cardiovascular disease, reducing all-cause mortality and cardiovascular events in many disease states. Studies have also suggested...
Articles
Articles
Clin Sci (Lond) (2007) 112 (1): 69–76.
Published: 01 December 2006
... treatment may be selectively controlling pancreatic islet blood flow, augmenting insulin secretion and thereby improving glucose tolerance. Our findings indicate significant gender-related differences in the vascular response to these agents. Since statins and renin–angiotensin system inhibitors...
Articles
Clin Sci (Lond) (2006) 111 (1): 87–91.
Published: 14 June 2006
... in smokers with normal lipid levels can be improved by a statin treatment. Correspondence: Dr Stefan Agewall (email stefan.agewall@karolinska.se ). 9 2 2006 27 3 2006 12 4 2006 12 4 2006 The Biochemical Society 2006 atherosclerosis cholesterol endothelial function...
Articles
Clin Sci (Lond) (2005) 108 (6): 493–495.
Published: 24 May 2005
....0000159890.10526.1e 17 Seeger F. H. Haendeler J. Walter D. H. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells Circulation 2005 111 1184 1191 18 Ridker P. M. Cannon C. P. Morrow D. C-reactive protein levels and outcomes after statin...
Articles
Articles
Articles
Articles
Articles